PrecisemAb Biotech is grateful to have completed an intensive and highly rewarding week through SelectUSA and the San Francisco startup ecosystem activities.
Over the course of the week, PrecisemAb Biotech had the valuable opportunity to participate in multiple pitch sessions, engage with investors, industry professionals, and innovation ecosystem partners, and share our vision for advancing safer and more selective antibody therapeutics through our Antibody Lock platform.
We are also honored that PrecisemAb Biotech was selected as one of the final six companies in the SelectUSA Health Tech Pitch. Although we did not advance as the category winner to the final competition, the experience was highly meaningful for our team. It allowed us to further refine our message, receive valuable feedback from international stakeholders, and validate the global relevance and potential of our technology.
We would like to sincerely thank the Small and Medium Enterprise and Startup Administration, Ministry of Economic Affairs, the American Institute in Taiwan (AIT), ITRI, and TAcc+ for their strong support throughout this journey. Their guidance, resources, and encouragement made this experience both inspiring and valuable as we continue to explore international opportunities and advance our mission to develop safer antibody therapeutics for patients worldwide.
News: Taisounds , Economic Daily News